Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608876

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608876

Neuralgia Treatment Market, By Drug Type (Anticonvulsants, Antidepressants, Opioids, Non-steroidal anti-inflammatory Drugs, and Others), By Route of Administration, By Severity, By Distribution Channel, By Geography

PUBLISHED:
PAGES: 172 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

The global neuralgia treatment market is estimated to be valued at USD 2.41 Bn in 2024 and is expected to reach USD 3.72 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: 2.41 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 6.40% 2031 Value Projection: 3.72 Bn
Figure. Neuralgia Treatment Market Share (%), By Region 2024
Neuralgia Treatment Market - IMG1

Neuralgia, also known as neuropathic pain, is a chronic pain caused by damage or disease affecting the somatosensory nervous system. It is characterized by shooting, stabbing, and sharp pain that feels exaggerated or unpredictable. Some common types of neuralgia include trigeminal neuralgia, postherpetic neuralgia caused by shingles, and fibromyalgia. The global neuralgia treatment market has been witnessing growth in recent times owing to the rising prevalence of neuropathic pain disorders and growing geriatric population who are more prone to such conditions. Furthermore, the development of novel drugs providing improved efficacy and minimal side effects are also fueling the demand for neuralgia treatments.

Market Dynamics:

The global neuralgia treatment market is driven by the increasing incidence of neuropathic pain disorders coupled with the growing geriatric population globally. Neuropathic pain conditions are more prevalent in the elderly due to age-related degenerative changes in the nervous system. Additionally, the market growth is facilitated by the development of newer drugs offering enhanced efficacy and favorable safety profiles over conventional treatment options. Carbamazepine and gabapentin are off-patent drugs commonly used to treat neuralgia. However, their tolerability issues lead to poor compliance. This has triggered R&D of novel therapeutic classes like sodium channel blockers, NMDA receptor antagonists, and alpha-2 delta ligands that demonstrate improved risk-benefit ratios. On the other hand, lack of disease-modifying treatments and high cost of newer therapies are some challenges restraining the market expansion to a certain extent. Nevertheless, rise in awareness about pain management and availability of generic versions of branded drugs create huge opportunities for the neuralgia treatment market players in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global neuralgia treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global neuralgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GlaxoSmithKline PLC, Pfizer Inc., Novartis AG, Biogen, Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Amgen Inc., Eli Lilly and Company, Astellas Pharma Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., and H. Lundbeck A/S.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global neuralgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuralgia treatment market

Market Segmentation

  • Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Anticonvulsants
    • Antidepressants
    • Opioids
    • Non-steroidal anti-inflammatory Drugs (NSAIDs)
    • Others
  • Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
    • Oral
    • Intravenous
    • Transdermal
    • Others
  • Severity Insights (Revenue, USD Bn, 2019 - 2031)
    • Mild
    • Moderate
    • Severe
  • Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • GlaxoSmithKline PLC
    • Pfizer Inc.
    • Novartis AG
    • Biogen
    • Cadila Healthcare Limited
    • Lundbeck Pharmaceuticals LLC
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi S.A.
    • Amgen Inc.
    • Eli Lilly and Company
    • Astellas Pharma Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Lundbeck A/S
Product Code: CMI7492

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Neuralgia Treatment Market, By Drug Type
    • Global Neuralgia Treatment Market, By Route of Administration
    • Global Neuralgia Treatment Market, By Severity
    • Global Neuralgia Treatment Market, By Distribution Channel
    • Global Neuralgia Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Neuralgia Treatment Market, By Drug Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Anticonvulsants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Opioids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Non-steroidal anti-inflammatory Drugs (NSAIDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Neuralgia Treatment Market, By Route of Administration, 2019-2031 (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Transdermal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Neuralgia Treatment Market, By Severity, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Mild
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Moderate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Severe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Neuralgia Treatment Market, By Distribution Channel, 2019-2031 (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Neuralgia Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • GlaxoSmithKline PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Biogen
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cadila Healthcare Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Lundbeck Pharmaceuticals LLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Amgen Inc.
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Lundbeck A/S

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!